Gargallo-Fernández, M.A.; Sanz-Pastor, A.G.; Antón-Bravo, T.; Brito-Sanfiel, M.; Wong-Cruz, J.; Gorgojo-MartÃnez, J.J.
Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study. Diabetology 2021, 2, 165-175.
https://doi.org/10.3390/diabetology2030015
AMA Style
Gargallo-Fernández MA, Sanz-Pastor AG, Antón-Bravo T, Brito-Sanfiel M, Wong-Cruz J, Gorgojo-MartÃnez JJ.
Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study. Diabetology. 2021; 2(3):165-175.
https://doi.org/10.3390/diabetology2030015
Chicago/Turabian Style
Gargallo-Fernández, Manuel A., Alba Galdón Sanz-Pastor, Teresa Antón-Bravo, Miguel Brito-Sanfiel, Jaime Wong-Cruz, and Juan J. Gorgojo-MartÃnez.
2021. "Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study" Diabetology 2, no. 3: 165-175.
https://doi.org/10.3390/diabetology2030015
APA Style
Gargallo-Fernández, M. A., Sanz-Pastor, A. G., Antón-Bravo, T., Brito-Sanfiel, M., Wong-Cruz, J., & Gorgojo-MartÃnez, J. J.
(2021). Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study. Diabetology, 2(3), 165-175.
https://doi.org/10.3390/diabetology2030015